Personalized Medicine Partnering Terms and Agreements

May 18, 2012 - PRLog -- Personalized Medicine Partnering Terms and Agreements provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies

Trends in personalized medicine partnering deals including:
Companion diagnostics
Pharmacogenomics
Biomarkers
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers"

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a review of the leading companion diagnostic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a review of the leading pharmacogenomic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of pharmacogenomic partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

for further information visit http://www.reportreserve.com/report/personalized-medicine...